GlassScriptPhysician profile
Kelsey Cobb
NPI 1336534064
$1,914.53
in general payments reported to CMS, 2019-2025
22 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $466 · 2022: $395 · 2023: $540 · 2024: $245 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $296.79 | 2021-2025 | Mounjaro, Zepbound |
| Amgen INC. | $259.24 | 2021-2025 | Repatha, Evenity, Otezla |
| Novartis Pharmaceuticals Corporation | $239.60 | 2022-2025 | |
| Abbvie INC. | $210.59 | 2021-2025 | |
| Novo Nordisk INC | $179.38 | 2021-2025 | Wegovy |
| Glaxosmithkline, LLC. | $137.77 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Mylan Specialty L.P. | $123.98 | 2021-2023 | Yupelri |
| Sumitomo Pharma America, INC. | $96.64 | 2023-2025 | Gemtesa |
| Esperion Therapeutics, INC. | $46.68 | 2023-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.74 | 2021-2022 | |
| Pfizer INC. | $32.46 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $29.13 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $27.68 | 2021-2022 | |
| Dynavax Technologies Corporation | $26.97 | 2022 | |
| Sunovion Pharmaceuticals INC. | $26.76 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $26.13 | 2025 | Eterna |
| Viatris Specialty LLC | $23.74 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $20.74 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.38 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $19.18 | 2022 | |
| Daiichi Sankyo INC. | $17.48 | 2021 | |
| Ibsa Pharma INC. | $17.47 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.